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ARTICLEAn X-Linked Myopathy with Postural Muscle Atrophy
and Generalized Hypertrophy, Termed XMPMA,
Is Caused by Mutations in FHL1
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Birgit Lohberger,5 Natalie Farra,1 Erwin Petek,2 Thomas Schwarzbraun,2 Lisa Ofner,2
Wolfgang N. Lo¨scher,6 Klaus Wagner,2 Hanns Lochmu¨ller,3 John B. Vincent,1 and Stefan Quasthoff5
We have identiﬁed a large multigenerational Austrian family displaying a novel form of X-linked recessive myopathy. Affected individ-
uals develop an adult-onset scapulo-axio-peroneal myopathy with bent-spine syndrome characterized by speciﬁc atrophy of postural
muscles along with pseudoathleticism or hypertrophy and cardiac involvement. Known X-linked myopathies were excluded by sim-
ple-tandem-repeat polymorphism (STRP) and single-nucleotide polymorphism (SNP) analysis, direct gene sequencing, and immunohis-
tochemical analysis. STRP analysis revealed signiﬁcant linkage at Xq25–q27.1. Haplotype analysis based on SNP microarray data from
selected family members conﬁrmed this linkage region on the distal arm of the X chromosome, thereby narrowing down the critical
interval to 12 Mb. Sequencing of functional candidate genes led to the identiﬁcation of a missense mutation within the four and
a half LIM domain 1 gene (FHL1), which putatively disrupts the fourth LIM domain of the protein. Mutation screening of FHL1 in a my-
opathy family from the UK exhibiting an almost identical phenotype revealed a 3 bp insertionmutation within the second LIM domain.
FHL1 on Xq26.3 is highly expressed in skeletal and cardiac muscles. Western-blot analysis of muscle biopsies showed a marked decrease
in protein expression of FHL1 in patients, in concordance with the genetic data. In summary, we have to our knowledge characterized
a new disorder, X-linked myopathy with postural muscle atrophy (XMPMA), and identiﬁed FHL1 as the causative gene. This is the ﬁrst
FHL protein to be identiﬁed in conjunction with a human genetic disorder and further supports the role of FHL proteins in the devel-
opment and maintenance of muscle tissue. Mutation screening of FHL1 should be considered for patients with uncharacterized myop-
athies and cardiomyopathies.Introduction
Myopathies are inherited muscle disorders characterized
by weakness and atrophy of voluntary skeletal muscle,
and several types of myopathy also show involvement of
cardiac muscle. Different forms of myopathy vary with re-
spect to pattern of inheritance, age of onset, incidence, rate
of progression, and ﬁnally, distribution and severity of
muscle weakness. Several myopathies exhibit an X reces-
sive mode of transmission. Duchenne muscular dystrophy
(DMD; Xp21.2; MIM #310200), the most common
X-linked myopathy, is mainly caused by frameshift muta-
tions that result in the complete absence of functional dys-
trophin, whereas the less severe Becker MD (BMD; MIM
#300376) is typically associated with missense and in-
frame deletions that result in reduced levels of functional
dystrophin, or expression of partially functional protein.1
DMD is correlated with onset before age 6 and a typical
life span of 20-25 years; in contrast, BMD has onset in
adolescence or adulthood, with symptoms similar to but
generally less severe than DMD. Both DMD and BMD pres-
ent with progressive muscle wasting with limb-girdle dis-
tribution, pseudohypertrophy of the calf muscles, and
frequently, cardiomyopathy. Emery-Dreifuss MD (EDMD;88 The American Journal of Human Genetics 82, 88–99, January 200MIM #310300) is another form of adult-onset X recessive
MD caused by deﬁciencies in the emerin protein, encoded
by the EMD gene on Xq28.2 EDMD is phenotypically dis-
tinct from other X-linked MDs, with pronounced contrac-
tures, rigid spine, a humeroperoneal distribution of muscle
wasting, and frequently, cardiomyopathy. X-linked myop-
athy with excessive autophagy (XMEA; MIM %310440)
also maps to Xq28 and shows progressive atrophy of skel-
etal muscles with no cardiac involvement, and an analysis
of biopsied muscle ﬁbers shows excessive autophagy and
exocytosis.3 Finally, an X-linked multisystem disorder,
McLeod syndrome, affecting red blood cells, the peripheral
and central nervous systems, and skeletal and cardiac mus-
cle, maps to Xp21.2–p21.1 (MIM 314850).4
In this study, a large multigenerational Austrian family
was identiﬁed, and six living affected members were ascer-
tained and examined. Pedigree analysis (Figure 1) is com-
patible with an X-linked recessive pattern of inheritance.
We describe the clinical delineation of a new muscular dis-
ease, along with genetic studies to identify the underlying
cause and molecular studies to show how the identiﬁed
gene and encoded protein might contribute to the disease.
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Figure 1. Pedigree of the X-Linked Myopathy with Postural Muscle Atrophy Families
(A) Only the core pedigree is shown here. Affected males are indicated by filled squares. The patient from the Schwarzmeier et al.5 study is
indicated with an arrow.
(B) The second XMPMA family, from the UK, is shown. The index patient is marked with an arrow.single case was published because the unusual phenotype
could not be classiﬁed. This patient was reported to show
a progressive muscular dystrophy of pelvicofemoral and
scapulohumeral type that was different from all other
known muscle dystrophies.5 The muscle pathology had
some similarities with myotonic dystrophy 1; however,
this was ruled out because no myotonic reaction was ob-
served. Finally, signiﬁcantly lowered Mg2þ-ATPase levels
were reported; however, the pathology did not suggest
any known metabolic myopathy.
In the extended family of this patient, many members
are affected by a distinct form of adult-onset X-linked reces-
sive myopathy with several features in commonwith other
MDs, but the presentation of a pseudoathletic phenotype,
scapuloperoneal weakness, and bent spine is unique and
might render the clinical phenotype distinguishable from
other myopathies. Further, immunohistochemical analysis
of muscle tissue revealed no deﬁciency in proteins asso-
ciated with known MDs, either autosomal or X-linked,
including dystrophin and emerin. On the basis of striking
similarities of the unique phenotypical presentation of the
Austrian family, we were able to recruit an additional fam-
ily originating from the UK for our genetic study.ThMaterial and Methods
Clinical Assessment
Probands were identiﬁed from amultigenerational Austrian family
(Figure 1) displaying clinical features suggesting MD, but with
clinical differences from previously described myopathies. Institu-
tional-research ethics-board approval for study of the family was
obtained. Patients and family members were recruited after giving
informed, written consent. We identiﬁed six living patients (all
males). Full neurological examination, including nerve conduc-
tion velocity (NCV) testing and electromyography (EMG), was
performed on all affected individuals included in the study (Table
1). Serum creatine kinase (CK) levels were also measured in af-
fected individuals (Table 1). First-degree relatives were examined
when possible, and genealogical data were also collected. Three
out of the six patients have been followed up for approximately
5 years for evaluation of disease progression. A second myopathy
family, ascertained through the Institute of Human Genetics,
Newcastle upon Tyne, UK, was also investigated because of a dis-
tinct similarity in symptoms with the Austrian family (Figure 1).
Muscle Biopsy
All muscle specimens were processed with standard histological
procedures. One part of the biopsy was embedded in parafﬁn,e American Journal of Human Genetics 82, 88–99, January 2008 89
Table 1. Clinical Evaluations for Members of the XMPMA Family from Austria
Patients ID
Age of
Onset
CKa Level
(U/L) EMGb
Muscle
MRIc
Athletic Habitus
in Early Stages
Muscle
Biopsy
Cardiac and Lung
Involvement
Neck and
Achilles Tendons
45 26 620 myopathic N.D.d yes N.D. unknown unknown
I.P.e 30 500-900 myopathic N.D. yes myopathic cardiomyopathy with
arrhythmia
short
20 32 620 N.D. selective MA,f BSg yes myopathic hypertrophic
cardiomyopathy
short
50 32 400-1774 myopathic selective MA, BS yes myopathic normal heart evaluation short
29 30 780 myopathic – yes N.D. unknown short
11 30 700 myopathic selective MA, BS yes myopathic hypertrophic
cardiomyopathy
short
59 31 550 myopathic N.D. unknown myopathic hypertrophic
cardiomyopathy
short
35 30 800-1200 myopathic N.D. yes myopathic respiratory failure short
I.P UK 35 1300 U/l normal N.D. yes myopathic respiratory failure short
This table includes electromyography, muscle magnetic resonance imaging (MRI), histological examination of biopsied tissue, and involvement of heart
and of neck and Achilles tendons. Patients’ IDs correspond to numbers given in Figure 1.
a CK represents creatine kinase level (normal <170 U/L).
b EMG stands for electromyography.
c MRI stands for magnetic resonance imaging.
d N.D. represents test not done.
e I.P. stands for index patient (described in Schwarzmeier et al.5).
f MA stands for muscle atrophy.
g BS stands for bent spine.and another was frozen in liquid nitrogen. Cryosections (8–10 mm)
were stained with hematoxylin and eosin, reduced nicotinamide
adenine dinucleotide-tetrazolium reductase, adenosine triphos-
phatase reactions at pH 4.6 and pH 10.4, modiﬁed Gomori tri-
chrome, van Gieson, cytochrome C oxidase, succinic dehydroge-
nase, Sudan black B, acid phosphatase, and periodic acid-Schiff.6
Magnetic Resonance Imaging
Muscle magnetic resonance imaging (MRI) was performed with
a 1.5 Tesla Siemens Avanto system (Graz, Austria). Magnet reso-
nance imaging of the axial and coronal planes of the spine and
upper and lower extremities, as well as the shoulder girdles,
with conventional T1-weighted spin echo (repetition time TR of
500 ms, echo time TE of 13 ms, with slight variations) and short
tau inversion recovery sequences was performed. The slices were
10 mm thick for the lower extremities and 6–10 mm thick for
the upper extremities, with an interslice gap of 6–10 mm. The
T1-weighted images were evaluated with regard to degree of mus-
cle atrophy (volume loss) and intramuscular fatty inﬁltration.
Electron Microscopy
Biopsy specimens for electron microscopy were ﬁxed in 6.25%
ice-cold glutaraldehyde in Sørensen’s 0.1 M phosphate buffer at
pH 7.3. After thorough rinsing in buffer, samples were postﬁxed
in 2% buffered osmium tetroxide. After rapid dehydration in
graded series of acetone, tissue blocks were embedded in Epon.
Semithin sections of the embedded blocks were stained with para-
phenylenediamine. Ultrathin sections were contrast enhanced
with uranyl acetate and lead citrate and examined with a Philips
400 T transmission electron microscope.
Muscle Immunocytochemistry
We used standard immunocytochemistry protocols to perform
staining for dystrophin, adhalin, merosin, dysferlin, caveolin, a-
dystroglycan, emerin, lamin A/C, desmin, b-slow myosin heavy90 The American Journal of Human Genetics 82, 88–99, January 20chain, spectrin, and a-sarcoglycan after muscle biopsies of
patient 50 (Figure 1). Monoclonal antibodies were obtained
from Novocastra Laboratories (Vision BioSystems) for spectrin
(NCL-SPEC1), dysferlin (NCL-Hamlet), emerin (NCL-Emerin), and
a-sarcoglycan (NCL-a-SARC). Additional Novocastra antibodies
were used for dystrophin staining, speciﬁc to the dystrophin rod-
like domain (NCL-DYS1), C terminus (NCL-DYS2), and N terminus
(NCL-DYS3). Monoclonal antibodies were employed for merosin
(MAB 1922; Chemicon), caveolin (Caveolin3; Transduction Labo-
ratories, BD Biosciences), a-dystroglycan (KlonVIA4-1; Upstate
Biotechnology, Europe), lamin A/C (Mouse Hybridoma Superna-
tant), desmin (M0760, Klon D33; Dako), and myosin (805-502-
L001, Lot L02279, Klon A4.951; Alexis Biochemicals) staining
procedures.
STRP Analysis
Genomic DNA was extracted from blood samples with standard
procedures. DNA was ampliﬁed by PCR with conditions adapted
from the ABI Prism Linkage Mapping Set v2.5 (MD10) protocol.
Denaturationwas performed at 95C for 15min and then followed
by ten cycles of 94C for 15 s, 55C for 15 s, and 72C for 30 s. This
was followed by 20 cycles of 89C for 15 s, 55C for 15 s, and 72C
for 30 s, with a ﬁnal extension step of 72C for 10 min. Reaction
mix consisted of 50 ng genomic DNA, 0.1 mmol of each primer,
and HotStar TaqMaster Mix (QIAGEN) in a reaction mix of 10 mL.
Haplotype analysis was performed with CYRILLIC v2.1 (Cyrillic
Software). Five intragenic STRP markers, DXS1238, DXS1237,
DXS997, DXS1236, and DXS1235, were selected for exclusion of
the DMD gene. The following additional markers spanning the
whole X chromosome were selected for linkage analysis:
DXS1060, DXS987, DXS1226, DXS1214, DXS1068, DXS993,
DXS991, DXS986, DXS990, DXS1106, DXS8055, DXS1001,
DXS1047, DXS6854*, DXS8094*, DXS1192*, DXS1232*,
DXS1227, DXS8043, DXS8091, and DXS1073 (markers identiﬁed
with an asterisk were selected from UCSC; all other markers were08
from the ABI Prism Linkage Mapping Set MD10). For the UCSC-
selected markers, forward primers were labeled at their 50 ends
with either 5-carboxyﬂuorescein (FAM) or NED ﬂuorochromes.
Primer sequences for the STRP markers are available from the
UCSC Genome Browser. Products were diluted and size-separated
with the ABI 3100 Genetic Analyzer (Applied Biosystems).
Linkage Analysis
Multipoint nonparametric linkage was computed with easy-
LINKAGE plus v5.02 platform7 and the ALLEGROprogram version
1.2c.8 Two-point linkage analysis was also performed with easy-
LINKAGE plus v5.02 and the SuperLink program version 1.5.9 Al-
lele frequencies were assumed to be equal and disease frequency
was set to 0.0001.
Genome-Wide SNP Analysis: Mapping of a New Locus
to Xq26–q27
A genome-wide 250K NspI Affymetrix SNP microarray (Affyme-
trix, CA, USA) analysis was performed on ﬁve affected individuals
(see Figure 1, pedigree members 20, 29, 50, 11, and 45) and three
unaffected relatives (28, 37, and 46), two of whom were obligate
carriers (37 and 46), at the Microarray Facility at The Centre for
Applied Genomics (Toronto, Canada). SNP microarray gene chip
data was subsequently analyzed with dCHIP software.10
Sequencing and Mutation Analysis
of Candidate Genes
Candidate genes within the Xq25–q27.1 12 Mb critical region
were identiﬁed via the UCSC genome browser and were selected
according to both tissue-expression proﬁle and known function.
The following four genes were chosen for mutation screening:
MBNL3, VGLL1, FGF13, and FHL1. Primers were designed with
the Primer3 program, and we used them to amplify all exons of
the functional candidate genes by PCRwith genomic DNA (primer
sequences available on request). PCR products were sequenced
with the BigDye Terminator 3.1 Cycle Sequencing Kit (Applied
Biosystems). Sequencing reactions were size-separated on the
ABI Prism 3100 DNAAnalyzer (Applied Biosystems), and sequence
data was collected with the ABI Data Collection software version
1.1 and subsequently analyzed with the ABI DNA Sequencing
Analysis version 3.6 software.
Immunohistology
Specimens of vastus-lateralis-muscle and anterior-tibial-muscle bi-
opsy (subjects 50 [vastus lat] and 11 [tib ant] from pedigree in Fig-
ure 1) were used for colocalization studies of FHL1 and myosin
slow ﬁber staining by indirect immunoﬂuorescence. In brief, after
ﬁxation with 2% para-formaldehyde, blocked with 4% BSA in PBS,
samples were combine stained with a polyclonal anti-rabbit FHL1
antiserum (dilution 1:1000 AVIVA Systems Biology) and monoclo-
nal anti-mouse skeletal slow myosin antiserum (dilution 1:5000,
Sigma, Germany) overnight at 4C temperature. After rinsing for
15 min in PBS, the sections were incubated with Cy3-conjugated
streptavidin goat anti-rabbit serum (Jackson-Immuno Research,
dilution 1:1000) and with Alexa-Fluor 488 goat anti-mouse serum
(Invitrogen). After the sections were mounted onto slides, a Leica
epiﬂuorescent microscope with a Zeiss Axiovert imaging system
was used for visualization. For comparison normal controls, as
well as limb-girdle muscular-dystrophy muscle, sections were in-
vestigated with identical procedures as described above. NegativeThcontrols with omission of the primary antibody did not show
any staining.
Immunohistochemistry on cultured muscle cells: primary myo-
blast cultures of vastus lateralis muscle and anterior tibial muscle
specimen (patients 50 and 11), and controls were used for FHL1
staining by indirect immunoﬂuorescence techniques. In brief,
after ﬁxation with 2% para-formaldehyde and blocking with 4%
BSA in PBS, samples were stained with a polyclonal rabbit FHL1
antiserum (dilution 1:1000 AVIVA Systems Biology) for 1 hr at
room temperature. After rinsing for 15 min in PBS, the sections
were incubated with Cy3-conjugated goat anti-rabbit serum (Jack-
son-Immuno Research, West Grove, PA, USA, dilution 1:1000).
After the sections were mounted onto slides, a Leica epiﬂuorescent
microscope with a Zeiss Axiovert imaging system was used for
visualization. Negative controls with omission of the primary
antibody did not show any staining.
Western Analysis
Forwestern-blot studies,proteinswere extracted from50mgof skel-
etal muscle from ﬁve normal controls, ﬁve disease controls (Becker
MD), and twomale patients (50 and 11). Protein concentrations of
the supernatants were measured with the BCA Protein Assay Kit
(Pierce). Samples were stored frozen at 80C. Aliquots of protein
(2 mg) were loaded onto a sodium dodecyl sulfate (SDS)-polyacryl-
amide gel, composed of 4% stacking (0.5 M Tris-HCL [pH 6.8] and
10% SDS) and 10% resolving (1.5 M Tris-HCL [pH 8.8] and 12%
SDS) gels. The protein was then transferred to nitrocellulose mem-
branes (Schleicher andSchuell) for1hr (110V).Nonspeciﬁcbinding
was blocked for 2 hr with TBST (10mMTris-HCL [pH 7.4], 140mM
NaCl, and 0.1% Tween-20) containing 5% skimmed milk; this was
followed by incubation with primary antibodies for 4 hr at room
temperature. Rabbit polyclonal antibody anti-FHL1 (AVIVA Sys-
tems Biology) was used at a dilution of 1:2000 in TBST-5% skim
milk. After washing, themembraneswere incubatedwith the corre-
sponding anti-rabbit or anti-mouse IgG secondary antibodies
(Dako) at a dilution of 1:1000 for 1 hr at room temperature. The
membranes were developed with the chemiluminescence ECL sys-
tem (Pharmacia) and then exposed to autoradiographic ﬁlm. Anal-
ysis of immunoreactive bands was performed semiquantitatively.
Blots were stripped and blots reincubated with mouse monoclonal
anti-adhalin antibody (Novocastra) at a dilution of 1: 2000.
Alignment of LIM-Domain Sequence
Alignmentofhomologousaminoacid sequences for theFHL1fourth
LIM domainwas performedwith the BOXSHADE program, with se-
quences fromhuman (NP_001440), orangutan (CAH91622), rhesus
monkey (XP_001103233), pig (NP_999540), mouse (NP_034341),
opossum (XP_001379179), platypus (translated from platypus
genomic Contig9.330), chicken (XP_001234114), zebraﬁsh
(XP_001334290), Xenopus tropicalis (NP_001006703), and tetraodon
nigroviridis (CAF92807).
Results
Clinical Assessment
Austrian Family
Clinical assessment in all six patients as well as two now-
deceased patients from this family (Figure 1A) revealed
a unique and characteristic phenotype (Table 1). During
the early stages of disease, all subjects showed an athletice American Journal of Human Genetics 82, 88–99, January 2008 91
appearance (Figure 2); however, detailed examination re-
vealed weakness and atrophy of postural muscles, whereas
other muscles appeared hypertrophic. Affected (atrophied)
muscles included the soleus, peroneus longus, tibialis ante-
rior, vastusmedialis, biceps femoris, erector spinae, and the
lower part of the latissimus dorsi. A list of muscle groups
that were atrophic, hypertrophic, or normal in affected in-
dividuals is given in Table 2 and shows that muscles with
predominantly type I ﬁber content are generally atrophic,
whereas muscles with predominantly type II ﬁbers are gen-
erally hypertrophic. Moreover, a mild scapular winging
was noted in all patients, to complete a scapulo-axio-pero-
neal syndrome. Additionally, all patients had signiﬁcant
contractures of the Achilles tendon and hamstrings, a short
neck, and also amechanically limited range of neck ﬂexion
and extension analogous to bent-spine syndrome. Tendon
reﬂexes, sensory examination, andmental status were nor-
mal. In all affected individuals scoliosis, back pain, gait
problems, and elevated creatine kinase levels were noted
(Table 1). Symptoms were not noted until ~30 years, and,
in six affected deceased family members, there was
a wide range in age of death (45–72 years), typically from
heart failure but of unknownmechanism. However, hyper-
trophic cardiomyopathy was suspected from earlier echo-
cardiographic investigation. Four- to ﬁve-year follow up
of three of the six affected patients showed an interindivid-
ually variable but slow progression of the disease.
UK Family
A second family, of British origin, with a putative diagnosis
of Becker muscular dystrophy was identiﬁed (Figure 1B).
The index patient presented initially with symptoms of
hip-ﬂexor weakness (MRC 4) and elevated serum CK levels
of ~1300 U/l at the age of 35 years. At that time, he was
playing competitive football and showed a very athletic
habitus. Muscle hypertrophy was most prominent in his
shoulder girdle and arm muscles. Neck ﬂexion was com-
promised by spinal rigidity. His lung function showed
a FVC of 4.6 l (90%) in a sitting position and dropped to
4.0 l (78%) in a lying position. There were no additional
clinical signs or symptoms of an underlying skeletal mus-
cle or heart disease. Nerve-conduction studies and an
EMG were normal. A muscle biopsy from the vastus later-
alis showed type I ﬁber atrophy, variation in ﬁber size,
with some measuring up to 125 mm in diameter, and a
few necrotic ﬁbers. Immunohistochemical and western-
blot analysis for proteins of the dystrophin glycoprotein
complex, emerin, dysferlin, caveolin, and calpain were
normal. Mutation analysis of the genes for dystrophin
and emerin did not reveal any abnormalities. Thematernal
grandfather of the index patient started to experience dif-
ﬁculties with walking at 42 years of age and used a wheel-
chair for the last years of his life. He died of respiratory fail-
ure at 52 with the label of Becker muscular dystrophy. Two
nephews of the grandfather were also labeled as Becker
muscular dystrophy and experienced slowly progressive
muscle weakness in legs and arms from their early 40s.
One of the nephews died in his 50s of respiratory failure.92 The American Journal of Human Genetics 82, 88–99, January 200Histological Analysis
Muscle histology revealed a moderate degenerative myop-
athy with a moderate perimysial and limited endomysial
Figure 2. Phenotype and Histological Findings of Patient 20
The clinical phenotype is composed of a scapulo-axio-peroneal
syndrome with an athletic appearance. Predominant shoulder gir-
dle atrophy with scapular winging and axial muscular atrophy of
postural muscles is found in the patients (A and B). Muscle biopsies
show moderate degenerative myopathy. In addition, a few round
autophagic vacuolar changes are apparent. H & E stain is shown
in (C) and (D). ATPase (pH. 9.4) is shown in (E). Increase in
fiber-size variation with hypertrophy of type 2 fibers (arrow in
[E]) and atrophy of both fiber types is seen (dark stained fibers cor-
respond to type 2 fibers). In the NADH staining (F), some core-like
NADH-negative central zones are seen (arrow in [F]). Immunohis-
tology with monoclonal antibodies against desmin (G) of speci-
mens from patient 50 showed positive staining in core-like lesions
(arrow and insert in [G]), and some subsarcolemmal desmin accu-
mulation. Electron microscopy of the muscle from patient 1 shows
an autophagic vacuole with autophagic debris including myelin-
like figures (H). White scale bars in (C)–(G) adjusted to 30 mm.
Magnification 3 3300 is shown in (H).8
Table 2. Muscle Involvement in XMPMA Patients
Muscle
Average Muscle-Fiber Composition
Type I Type II Atrophic Hypertrophic Normal
Abductor digiti minimi 51.8 48.2 X
Abductor pollicis brevis 63.0 37.0 X
Abductor hallucis X
Adductor magnus (Deep) 63.3 36.7 X
Biceps brachii (Surface) 42.3 57.7 X
Biceps brachii (Deep) 50.5 49.5 X
Biceps fernoris 66.9 33.1 X
Brachioradialis 39.8 60.2 X
Deltoideus (Surface) 53.3 46.7 X
Deltoideus (Deep) 61.0 39.0 X
I dorsal interosseus 57.4 42.6 X
Erector spinae (Surface) 58.4 41.6 X
Erector spinae (Deep) 54.9 45.1 X
Extensor digitorum 47.3 52.7 X
Extensor digitorum brevis 45.3 54.7 X X
Flexor digitorum brevis 44.5 55.5 X
Flexor digitorum profundus 47.3 52.7 X
Gastrocnemius (Lateral head, surface) 43.5 56.5 X
Gastrocnemius (Lateral head, deep) 50.3 49.7 X
Gastrocnemius (Medial head) 50.8 49.2 X
Gluteus medius X
Gluteus maximus 52.4 47.6 X
Iliocostalis X
Interspinales cervicis X
Infraspinatus 45.3 54.7 X
Longus capitis X
Longus colli X
Longisimus dorsi X
Latissimus dorsi 50.5 49.5 X
Multifidus X
Orbicularis oculi 15.4 84.6 X
Obliqus capitis X
Peronaeus longus 62.5 37.5 X
Psoas X
Rectus abdominis 46.1 53.9 X
Rectus femoris (Lateral head, surface) 29.5 10.5 X
Rectus femoris (Lateral head, deep) 42.0 58.0 X
Rectus femoris (Medial head) 42.8 57.2 X
Rhomboideus 44.6 55.4 X X
Semimembranosus X
Semispinalis X
Soleus (Surface) 86.4 13.6 X
Soleus (Deep) 89.0 11.0 X
Splenius X
Sternocleidomastoideus 35.2 64.8 X X
Supraspinatus 59.3 40.7 X
Temporalis 46.5 53.5 X
Tibialis anterior (Surface) 73.4 26.6 X
Tibialis anterior (Deep) 72.7 27.3 X
Trapezius 53.7 46.2 X X
Triceps surae X
Triceps (Surface) 32.5 67.5 X
Triceps (Deep) 32.7 67.3 X
Vastus lateralis (Surface) 37.8 62.2 X
Vastus lateralis (Deep) 46.9 53.1 X
Vastus medialis (Surface) 43.7 56.3 X
Vastus medialis (Deep) 61.5 38.5 X
This tablewas adapted fromJohnsonet al.29 and indicates (by ‘‘X’’) whether, by clinical examinationof all six living patients aswell as byMRIof threepatients in
progressed stages of disease, abnormality is present, either atrophic or hypertrophic. Muscles represented in italics normally display significantly high portion
of type Imuscle fibers; however, in the XMPMApatients, the posturalmuscles—adductormagnus, biceps femoris, deltoideus, peronaeus longus, soleus, tibialis
anterior, and vastus medialis—showed gradual atrophy, whereas many muscles with a high percentage of fiber type II show mild to pronounced hypertrophy.The American Journal of Human Genetics 82, 88–99, January 2008 93
ﬁbrosis. Centrally placed myonuclei were increased, and
rarely single-ﬁber necrosis and granular myoﬁber degener-
ation were seen (ﬁber-size variation was increased in all
specimens with diameters ranging between 20 and 120 mm;
see Figure 2), and most prominent in type 2 ﬁbers. A few
autophagic vacuoles predominant in type 2 ﬁbers were
detectable (Figure 2). In NADH and COX histochemistry,
centrally negative core-like lesions were detected (Figure 2),
without any further mitochondrial alterations. Electron
microscopy revealed autophagic vacuoles with myelin-
like debris (Figure 2). Immunohistology showed pro-
nounced antidesmin staining in the core-like zones (Fig-
ure 2). All additional cytoskeletal immunohistochemistry
were completely normal (data not shown).
Exclusion of Known Myopathies
Initial studies on index patients (50 and 11) with immuno-
cytochemical staining and western blotting excluded the
X-linked MDs (DMD, BMD, and EDMD), and numerous
autosomal limb-girdle MDs (1C, 2I, 2B, 2C, 2D, 2E, and
2F). Myotonic dystrophies type 1 and 2, Kennedy syn-
drome, and McLeod myopathy were excluded by molec-
ular-genetic analysis. Subsequently, a more detailed pedi-
gree was established, and analysis suggested that this
family displays a late-onset myopathy with X-linked reces-
sive inheritance. To exclude the possibility that the pheno-
type in these cases is a variant form of DMD or BMD, we
performed linkage analysis to the DMD locus by using
ﬁve selected STRP intragenic markers at the DMD gene:
DXS1238, DXS1237, DXS997, DXS1236, and DXS1235.
Different haplotypes were revealed except for marker
DXS1237 within our patients at the DMD locus, thereby
excluding this locus as the causative gene in this family
(Table 3). Subsequent screening for mutations in the DMD
gene was conducted by sequencing patient’s cDNA pro-
ximal to the ﬁrst recombination event (including exons
1–44), thereby adding further weight to the exclusion of
DMD. Thus, theDMD locus was ruled out by immunocyto-
chemistry, indirect DNA analysis, and direct DNA analysis.
In order to exclude desminopathies, which share some
of the phenotypic features observed in these two families,
we performed immunocytochemical analysis for desmin,
which was normal except in patient 11 (see Figure 1) who
displays the clinically most advanced status of disease
Table 3. Haplotype Analysis of the DMD Locus in Patients
from the Austrian Family
Marker
20 29 50 11 45 46
Allele Sizes (bp)
DXS1238 206 206 206 184 184 184/184
DXS1237 178 178 178 178 178 174/178
DXS997 115 115 115 115 115 107/113
DXS1236 251 233 233 239 235 233/239
DXS1235 245 245 245 245 245 233/235
Genotypes are given for patients 20, 29, 50, 11, and 45 (shaded) as well as
obligate carrier 46 (unshaded) (see Figure 1).94 The American Journal of Human Genetics 82, 88–99, January 20among the living familymembers. In his specimen of biop-
sied muscle, desmin staining showed reduced signal (data
not shown).
Genetic Analysis
Genotypes for STRP markers across the X chromosome
were analyzed. The threshold for statistically signiﬁcant
evidence of linkage of X-linked traits is Z > 2.0.11 Two-
point parametric LOD scores were calculated (DXS1047,
128.9 Mb, LOD ¼ 2.4; DXS8094, 136.1 Mb, LOD ¼ 3.3;
DXS1192, 138.2 Mb, LOD ¼ 3.4; and DXS1232, 139.1 Mb,
LOD ¼ 2.6; q ¼ 0 [distances according to UCSC March
2006 freeze]; see Table 4 and Figure 3).Multipoint, nonpara-
metric LOD scores were calculated, and gave a maximum
LOD score of 2.4 around DXS8094 (Figure 3). Haplotype
analysis was performed with CYRILLIC v2.1 (Cyrillic Soft-
ware, UK) (data available on request from the authors
[C.W.]). Recombination events in affected subjects and obli-
gate carriers allowed us to determine a commondisease hap-
lotype. The distal boundary is deﬁned by marker DXS1227
(140.6Mb), and the proximal boundary is deﬁnedbymarker
DXS8055 (114.6Mb), by recombinationevents in individual
20. Subsequently, we performed a genome-wide SNP geno-
type analysis (~250K; NspI Affymetrix chip) on ﬁve affected
individuals, two obligate carriers, and one unaffected in-
dividual. Hemizygosity mapping with dChip software10
conﬁrmed a 12 Mb shared disease haplotype for all affected
subjects and obligate carriers analyzed, on Xq25–q27.1,
which encompasses 407 consecutive SNPs (rs4614130
[126.569 Mb, Xq25] to rs5907636 [138.561 Mb, Xq27.1]).
Mutation Screening of Candidate Genes
Four candidate genes that are from the Xq26–q27 critical
region and that encode structural proteins expressed in
Table 4. Two-Point Linkage Analysis
Marker POS_cM 0 0.1 0.2 0.3 0.4
DXS986 57.383 17.6293 1.5459 0.8108 0.4359 0.1914
DXS990 60.622 8.8048 0.2483 0.0654 0.1219 0.079
DXS1106 68.742 3.9435 0.8234 0.8123 0.6214 0.3395
DXS8055 70.911 3.9537 0.5575 0.7252 0.6068 0.3481
DXS1001 75.791 1.9488 1.6479 1.2864 0.8843 0.4532
DXS1047 82.844 2.4266 2.0061 1.5388 1.0339 0.5078
DXS6854 82.8445 2.8794 2.3985 1.8633 1.2768 0.6483
DXS8094 82.854 3.3472 2.7653 2.1348 1.4531 0.7292
DXS1192 83.921 3.4417 2.8448 2.1943 1.4892 0.7434
DXS1232 85.55 2.5869 2.1928 1.7225 1.1925 0.6147
DXS1227 88.33 13.9949 0.111 0.2855 0.2194 0.1025
DXS8043 94.221 4.4146 0.7774 0.7002 0.4955 0.2517
DXS8091 97.891 10.8139 0.3899 0.4965 0.3574 0.1628
DXS1073 102.351 16.1018 1.123 0.3448 0.0628 0.0203
This table shows linkage data for X chromosome STRPs, analyzed with the
SuperLink program version 1.59 from easyLINKAGE plus v5.02. Allele fre-
quencies were assumed to be equal, and disease frequency was set to
0.0001. Positions of markers are indicated in centimorgans (cM), as pro-
vided by Marshfield. LOD scores for theta values of 0, 0.1, 0.2, 0.3, and
0.4 are shown. Significant LOD scores (>2) are shaded with dark gray,
and positive LOD scores are shaded with light gray.08
Figure 3. Two-Point Parametric and
Multipoint Nonparametric Linkage Anal-
ysis for the XMPMA Family
Linkage data for X chromosome STRPs, an-
alyzed with the SuperLink program version
1.59 from easyLINKAGE plus v5.02.7 Allele
frequencies were assumed to be equal,
and disease frequency was set to 0.0001.
Multipoint LOD scores were calculated
with ALLEGRO version 1.2c.8 Positions of
markers are indicated in centimorgan
(cM), as provided by Marshfield. Maximum
LOD scores are shown.muscle were screened. The muscleblind-like protein 3
(MBNL3), vestigial-like 1 (VGLL1), and ﬁbroblast growth
factor 13 (FGF13) genes were all sequenced from genomic
DNA, but no coding mutations were identiﬁed. Sequenc-
ing of the four and a half LIM domain 1 gene (FHL1,
NM_001449) identiﬁed a transversion at position 672
C/ G leading to the amino acid substitution cysteine to
tryptophan, C224W (Figures 4 and 5). This mutation cose-
gregated with disease status within the family; all six af-
fected subjects were hemizygous, and all obligate carriers
were heterozygous for the mutated allele. The mutation
was not detected in 402 mixed European ancestry and
570 Austrian control chromosomes, and was not present
either in published SNP databases or in published spliced
expressed sequence tag (EST) sequences. In the UK family,
mutation screening of FHL1 identiﬁed a 3 bp insertion
after nucleotide 381 (c.381_382insATC), leading to the
insertion of an isoleucine residue within the second LIM
domain (p.Phe127_Thr128insIle) (Figures 4 and 5). This
mutation was not detected in 570 Austrian chromosomes
and is not present in SNP databases.
Conservation Analysis
Box-shade alignment shows a high degree of conservation
of amino acid sequence for FHL1, and for the fourth LIM
domain in particular (Figure 4), across
all vertebrate species. Conservation of
cysteine residues is 100%. Also, the
number of amino acid residues be-
tween cysteine residues is highly con-
served, and at the location of the in-
sertion mutation in the second LIM
domain, there are two amino acids
between the cysteine residues in all
vertebrate species studied. This spac-
ing appears to be a consistent feature
of LIM-domain proteins. Homology
is also high between the vertebrate
FHL1 sequences and homologous se-
quences for nonvertebrates such as
C. elegans and Drosophila (data not
shown), and again, all cysteine residues are preserved, al-
thoughsequences for theseorganismsmightbemoreclosely
related to FHL2 and might thus represent an ancestral pro-
tein that later diverged into the different FHL proteins.
Western Analysis
Western blotting was performed a number of times, with
anti-FHL1 antibody showing almost complete absence of
the FHL1-protein band at 29 kDa in all patients compared
to normal and disease (MD) controls (Figure 6). The FHL1
band showed similar strength in disease controls (LGMD
and BMD) in comparison to healthy controls, thus im-
plying that reduction of FHL1 protein is not a common
feature of myopathy pathogenesis.
Immunohistochemical Analysis of FHL1
In skeletalmuscleofnormal controls, FHL1stainingrevealed
acheckeredexpressionpattern. Fibers coexpressingslowmy-
osin heavy chain showed relatively weak FHL1 expression,
whereas many, but not all, ﬁbers negative for slow myosin
heavy chain showed higher FHL1 expression. This indicates
that FHL1 is expressed in all muscle ﬁbers, although higher
levels are detected in a subset of fast-twitch muscle ﬁbers.
This pattern was identical in skeletal muscle of patients,
although the staining intensity was lower (Figure 6).The American Journal of Human Genetics 82, 88–99, January 2008 95
Immunohistochemistry of Primary HumanMyoblasts
In keeping with the immunoblot results, staining of cul-
tured, primary myoblasts of patient 50 for FHL1 revealed
a reduction of overall expression, but no overt aberration
of subcellular localization, as compared to normal controls
(Figure 7). In both, patient and control myoblasts FHL1
was expressed primarily in the cytoplasm.
Discussion
A new and phenotypically distinct X-linked myopathy,
XMPMA, has been described in this study, with the main
clinical presentation being atrophy of postural muscles
combined with a generalized hypertrophy. Although it is
clinically distinct, the possibility that the disorder might
be an allelic form of a knownX-linkedmyopathy was ruled
out by a combination of immunohistochemical and ge-
netic studies; X-linked myopathies excluded are DMD,
BMD, EDMD, and XMEA and also McLeod syndrome,
Figure 4. Ideogrammatic Representa-
tion of the XMPMA Locus on the Distal
Arm of Chromosome X, Genomic Orga-
nization, Mutation Identification, and
Protein Sequence of the FHL1 Gene
(A) The XMPMA locus on Xq26.3 is indicated,
alongwith the intron/exon structure of FHL1
isoforms A, B, and C. Protein sizes (kDa) for
the different isoforms were determined by
western hybridization by Brown et al.21 for
FHL1a and by Ng et al.22 for FHL1c.
(B) Electropherograms indicating the wild-
type andmutation sequence for the Austrian
and UK XMPMA families are shown, as well as
the secondary structure of FHL1, indicating
the position of the resulting amino acid
substitution, C224W, relative to structural
features in the protein.
(C) Amino acid sequence for FHL1a, indicat-
ing LIM domains that were underlined, and
Zn2þ-binding cysteine residues were indi-
cated in red type.
(D) Comparative analysis: Analysis of the
amino acid sequence for fourth LIM domain
of FHL1 across vertebrate species with BOX-
SHADE. Zn2þ-binding cysteine residues (*)
and the position of mutation Cys224Trp
(C224W) (*) are indicated. The domain and
cysteine residues are highly conserved
across vertebrates, from primates through
to amphibians and primitive fish.
Barth syndrome (Xq28; MIM
#302060), and myotubular myopa-
thy 1 (MTM1; Xq28; MIM #310400).
Linkage studies and haplotype analy-
sis led to the identiﬁcation of the
Xq25–q27.1 region for the XMPMA
locus, and four functional candidate genes were selected
from within this region and were screened for possible dis-
ease-relatedmutations. FHL1 on Xq26.3 was found to have
the amino acid substitution C224W segregating with dis-
ease in the Austrian family. Analysis of the protein by west-
ern blottingwith FHL1-speciﬁc antibodies indicated a strik-
ing reduction of FHL1 levels in patients’ muscle cells,
apparently corroborating the genetic ﬁndings. FHL1 pro-
tein, however, was not reduced in muscle tissue from pa-
tients with either Becker or LGMD, suggesting that reduc-
tion of FHL1 is not a common feature among myopathies.
FHL1 is expressed in skeletal and cardiac muscle, is more
abundant in oxidative ﬁbers (as shown in rat studies12),
and is suggested to play a role in sarcomere synthesis and
assembly.13 FHL1 has been shown to be involved in regu-
lation of muscle ﬁber type I development in ﬁsh.14 FHL1
is a member of LIM-only proteins, containing four and
a half LIM domains (named from the initials of the ﬁrst
three homeodomain proteins in which it was discovered:
LIN11, ISL1, and MEC315) with the FHL-speciﬁc LIM96 The American Journal of Human Genetics 82, 88–99, January 2008
consensus sequence C-X2-C-X16-21-H-X2-C-X2-C-X2-C-
X17-C-X2-C. LIM domains are cysteine rich, double-zinc
binding structures consisting of two subdomains, each
responsible for binding one Zn2þ ion. Metal ions are
known to stabilize the tertiary conformation of proteins.
Thus, the zinc ions help deﬁne the tertiary structure of
the LIM domain and thereby generate a binding interface
for proteins.16 The C224Wmutation replaces a highly con-
served cysteine within the fourth LIM domain of FHL1,
which is one of the four cysteines needed for the central
binding of a Zn2þ ion (Figure 4). Mutations at conserved
cysteines that are involved in zinc binding have been
shown to have a highly deleterious effect on the tertiary
structure of the protein.17 In vitro mutagenesis studies of
conserved Zn2þ-binding cysteines within LIM domains
have demonstrated that substitution results in diminished
Zn2þ-coordination and might eliminate the stability of the
LIM tertiary structure.18 Furthermore, in the progressive
neurodegenerative disorder Mohr-Tranebjaerg syndrome
(MIM #304700), a disease-causing cysteine-to-tryptophan
substitution within a Cys4 metal-binding motif of the
DDP1/TIMM8A gene was shown to ablate Zn2þ binding.19
In the muscle LIM protein (MLP or CSRP3), which is
known to be causative for hypertrophic cardiomyopathy
(CMD1M; MIM #607482), mutation of a Zn2þ-coordinat-
ing cysteine residue completely ablates the Zn2þ binding
for the second zinc ﬁnger within the ﬁrst LIM domain.
This leads to the protein being more unstable and vulner-
able to proteolysis, as well as reducing its protein-protein
interactions.20 Thus, it is very likely that mutations affect-
ing the Zn2þ-complexing property of FHL1 cause hypertro-
Figure 5. Isoforms of FHL1
The organization of tandem LIM domains, as well as nuclear local-
ization signals, nuclear export signals, and protein binding
domains for FHL1 isoforms A, B, and C are shown. The cDNA and
protein for each isoform are displayed alongside each other, with
cDNA size and the number of amino acids present in each isoform
being indicated on the right-hand side. The positions of the
mutations in the Austrian family (p.C224W) and UK family
(p.F127_T128insI) are shown relative to the three different FHL1
isoforms.Thphy of skeletal as well as cardiac muscles, analogous to the
situation with MLP causing hypertrophy of cardiac muscle
in HCM. The UK mutation results in the insertion of an
isoleucine residue between the two amino acid residues
(127 to 128) that link the two Zn2þ ﬁngers of the second
LIM domain and is likely to disrupt the protein conforma-
tion. The consensus C-X2-C spacing of the subdomains in
Figure 6. Western Blot and FHL1/Myosin Slow Immunofluo-
rescence
(A) FHL1 western blotting: In specimens from patients 50 and 11
(P1 and P2), a normal control (Co), and controls with either Becker
MD (BMD) or limb girdle MD (LGMD), the specific FHL1 band at
29 kDa is severely reduced compared to normal and disease con-
trols. The 50 kDa band corresponds to alpha-sarcoglycan (adhalin)
showing equal quantity of protein loading in all samples.
(B) Anti-FHL1 and anti-myosin slow-type immunofluorescence of
human muscle from two patients with FHL1 mutation. The top row
showscontrol samples: Overlay shows that FHL1 (red) does not coloc-
alize to myosin slow type (green). Shown in the middle row: An over-
lay in a patient with FHL1 mutation reveals nearly complete loss of
FHL1 staining. Shown in the bottom row: Overlay in a patient with
FHL1mutation shows a very few remaining anti-FHL1-positive fibers.
Figure 7. Expression Analysis of FHL1 in Primary Human
Myoblasts
Anti-FHL1 staining in primary myoblasts from control (Co) and
from patient 50 (P1). The patient’s myoblasts show lower expres-
sion of FHL1, but subcellular distribution is not different to con-
trol. Both patient and control show primarily cytoplasmic but
also nuclear FHL1 distribution.e American Journal of Human Genetics 82, 88–99, January 2008 97
LIM proteins is highly conserved across evolution. Thus,
the altered distance between the two Zn2þ ﬁnger subdo-
mains is expected to have an adverse effect on the pro-
tein-protein binding properties of the LIM domain.
FHL1 has at least three different isoforms, which differ in
their amino acid sequence, expression pattern, binding part-
ners, and subcellular localization: isoform A (FHL1A, SLIM1,
and Q13642-1 [ExPASy number]) is abundantly expressed,
with highest levels in skeletal muscle, and intermediate ex-
pression inheart, and low-level expression inplacenta, ovary,
prostate, testis, small intestine, and colon; isoformB (FHL1B,
SLIMMER, andQ13642-2) is abundantlyexpressed in skeletal
muscle, with lower expression in heart, colon, prostate, and
small intestine (from Northern hybridization analysis21);
and isoform C (FHL1C and Q13642-3) is expressed at much
lower levels compared to FHL1A, in testis, heart, and skeletal
muscle (from Northern hybridization analysis22).
The C224Wmutation affects FHL1 isoforms A (the most
prevalent isoform22) and B but not C. The isoleucine inser-
tion mutation in the UK family affects all three isoforms.
FHL1A and FHL1B are identical until amino acid residue
230, beyond which alternative splicing results in the
fourth LIM domain being replaced by sequences for nu-
clear/cytoplasmic shuttling and transcription-factor bind-
ing in FHL1B (Figure 5). Thus, the functional consequences
of C224W on FHL1A and FHL1B are expected to be differ-
ent: Whereas C224W is likely to disrupt the Zn2þ-binding
properties of FHL1A, in FHL1B, the mutation is located
within the ﬁrst nuclear localization sequence (NLS1) and
thus might result in impaired FHL1B shuttling between
nucleus and cytoplasm.21 A number of protein binding
partners, including myosin-binding proteins MYBPC1
(slow type) and MYBPC3 (cardiac), as well as SRF and
ERK2, bind to different LIM domains within FHL1. Muta-
tions in MYBPC3 are the second most common cause of
familial hypertrophic cardiac myopathy.23,24 FHL1 is con-
sidered to be a regulator of MYBPC activity and thus in-
volved in sarcomere assembly.12 As a result of the different
protein-binding properties of the different LIM domains in
FHL1, mutations within the different domains might have
different phenotypic consequences. Another MYBPC1
binding partner is deleted inmuscular dystrophyKy knock-
downmice, which displaymyopathy with postural-muscle
weakness that leads to kyphoscoliosis and that results in
a shift from ﬁber type 2 to 1.25 Interestingly, in contrast to
the XMPMA patients, there is no evidence of hypertrophy
in these mice. We hypothesize that the twoMYBPC1-bind-
ing partners, Ky and FHL1, determine the composition of
muscle ﬁbers in skeletal muscles, and dysregulation might
lead to myopathies affecting postural muscles.
Involvement of axial muscles, rigidity of the spine, and
ankle contractures are prominent symptoms in a number
of skeletal muscle disorders such as selenoprotein 1, Lamin
A/C, and collagen-6-related myopathies.26 However, mus-
cle hypertrophy is not a common feature in these disorders.
Recently, desminmutationswere identiﬁed inpatientswith
a scapuloperonealmyopathywith axialmuscleweakness.2798 The American Journal of Human Genetics 82, 88–99, January 200The desmin protein accumulation detected inmuscle ﬁbers
of FHL1-mutated patients might suggest a similar patho-
physiological pathway as in desmin-related myopathies.
In summary, we have identiﬁed the gene FHL1, and its
encoded protein, as responsible for a new form of X-linked
recessive myopathy termed XMPMA. The phenotypic fea-
tures described in the Austrian and UK families, in particu-
lar the speciﬁc atrophy of postural muscles and pseudoath-
leticism, might be speciﬁc for mutations within the SRF
and MyBPC1 (muscle ﬁber type 1-speciﬁc isoform) and
ERK2-binding regions of FHL1. FHL1 is most likely to be
a modulator of skeletal muscle hypertrophy, as is the case
for FHL2 and CSRP3 in cardiac hypertrophy.28 We hypoth-
esize that mutations elsewhere in the gene are likely to
result in a more heterogeneous myopathic phenotype be-
cause of the binding-partner speciﬁcity of the different
LIM domains in FHL1, as well as the isoform-speciﬁcity
of various domains within FHL1. This has considerable im-
plications for diagnostic evaluation, screening, and genetic
counseling of patients (also carriers) with myopathy of
unknown genetic cause, particularly in cases such that
pedigree information would suggest X-linked inheritance,
but the Becker and Duchenne MD, Emery-Dreifuss MD,
XMEA, and McLeod are excluded. In addition, it has
been noted that cardiomyopathy is present in at least
four affected members of the large XMPMA family, and
thus the FHL1 gene might also be a strong candidate for
hereditary and sporadic cardiomyopathy.
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